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Clopidogrel Loading Dose Adjustment According
to Platelet Reactivity Monitoring in Patients
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Objectives We aimed to investigate the biological impact of a tailored clopidogrel loading dose (LD) according to platelet
reactivity monitoring in carriers of the cytochrome (CYP) 2C19*2 loss-of-function polymorphism undergoing per-
cutaneous coronary intervention for an acute coronary syndromes.
Background CYP2C19*2 polymorphism is associated with reduced clopidogrel metabolism and a worse prognosis after per-
cutaneous coronary intervention.
Method A prospective multicenter study enrolling 411 patients with non–ST-segment elevation acute coronary syndrome
undergoing percutaneous coronary intervention was performed. Platelet reactivity was measured using the
vasodilator-stimulated phosphoprotein (VASP) index, and a cutoff value of 50% was used to define high on-
treatment platelet reactivity (HTPR). The genetic polymorphism of CYP2C19 was determined by allele-specific poly-
merase chain reaction. In patients carrying CYP2C19*2 and exhibiting HTPR after a first 600-mg LD of clopidogrel,
dose adjustment was performed by using up to 3 additional 600 mg LDs to obtain a VASP index 50%.
Results One hundred thirty-four patients (35.3%) carried at least one 2C19*2 allele (11 homozygotes [2.7%] and 123 heterozy-
gotes [32.6%]). The VASP index in these patients was significantly higher than in homozygotic patients for the wild-type
alleles (61.7 18.4% vs. 49.2 24.2%; p 0.001). Of the 134 carriers of the loss-of-function polymorphism, 103 were
considered to have HTPR. After a second clopidogrel LD, the VASP index was significantly decreased in these patients (69.7
 10.1% vs. 50.6 17.6%; p 0.0001). Finally, dose adjustment according to platelet reactivity monitoring, enabled
88% of 2C19*2 carriers exhibiting HTPR to reach a VASP index 50%.
Conclusions Increased and tailored clopidogrel loading dose according to platelet reactivity monitoring overcome HTPR in
carriers of the loss-of-function CYP2C19*2 polymorphism. (J Am Coll Cardiol 2010;56:1630–6) © 2010 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.07.004H
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ccepted July 7, 2010.igh on-treatment platelet reactivity (HTPR) after a clo-
idogrel loading dose (LD) has been shown to predict the
hort- and long-term prognoses in patients undergoing
ercutaneous coronary intervention (PCI) (1–3). It has been
emonstrated that the level of platelet reactivity inhibition
PRI) after a clopidogrel LD strongly correlates with post-
CI outcome, particularly with early stent thrombosis (3).
See page 1637
he vasodilator-stimulated phosphoprotein (VASP) index has
een used in several studies to assess clopidogrel responsiveness
4–6). It is the most specific platelet assay to evaluate P2Y12
denosine diphosphate (ADP) receptor activity and thus the
ffect of clopidogrel on platelets (7,8). Importantly studies have
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November 9, 2010:1630–6 Clopidogrel Dose Adjustment in 2C19*2 Carriersonstantly reported the same cutoff value of the VASP index to
redict post-PCI thrombotic events of 50% (4–6). This cutoff
alue was shown to have a very high negative predictive value
sing receiver-operator characteristic curve analysis in several
rials. In a recent consensus article on the definition of HTPR,
his cutoff value (VASP index 50%) was suggested to be of
linical significance and could thus be used as a surrogate end
oint (9).
Clopidogrel is a prodrug that necessitates biotransformation
y hepatic cytochromes (CYPs) into its active metabolites.
ecent studies underlined the critical role of the CYP2C19*2
olymorphism in the biological response to clopidogrel and
hus in the rate of patients with HTPR (10–14). Carriers of
his loss-of-function polymorphism have reduced active me-
abolite generation and therefore suboptimal PRI, which in
urn results in a higher rate of thrombotic events post-PCI,
articularly early stent thrombosis (12,13).
We previously demonstrated that a tailored LD of clopi-
ogrel according to PRI in patients with HTPR can
mprove the level of PRI, resulting in improved clinical
utcomes (15,16). However, it remains unknown whether
uch a strategy is effective in carriers of the loss-of-function
YP2C19*2 polymorphism. In the present study, we aimed
o evaluate a strategy of clopidogrel LD adjustment accord-
ng to PRI monitoring in carriers of CYP2C19*2 loss-of-
unction polymorphism exhibiting HTPR.
ethods
prospective multicenter study was performed. All patients
ndergoing PCI for non–ST-segment elevation acute coronary
yndrome were eligible. Non–ST-segment elevation acute
oronary syndrome was defined as clinical symptoms compat-
ble with acute myocardial ischemia within 12 h before admis-
Figure 1 Flowchart of the Study
ACS  acute coronary syndrome; Failure  failed dose adjustment according
to platelet reactivity monitoring; Hmz  homozygotes; Htz  heterozygotes;
LD  loading dose; Success  successful dose adjustment according to plate-
let reactivity monitoring; VASP  vasodilator-stimulated phosphoprotein index.oion and at least 1 of the following:
new finding of ST-segment de-
ression 0.05 mV, T-wave in-
ersion 0.3 mV in at least 2
eads, or elevated levels of cardiac
arkers. The flow chart of the
tudy is shown in Figure 1. All
atients received oral LDs of 250
g aspirin and 600 mg clopidogrel
t least 6 h before the first VASP
ndex measurement. Dose adjust-
ent was performed before PCI in
ll patients.
Exclusion criteria were persis-
ent ST-segment elevation acute
oronary syndrome, failed PCI,
ew York Heart Association
unctional class III or IV, cardiac
rrest, contraindications to anti-
latelet therapy, a platelet count
100 g/l, history of bleeding di-
thesis, and concurrent severe ill-
ess with expected survival of1
onth.
Blood samples for VASP index analysis were drawn by
traumatic venipuncture of the antecubital vein between 6
nd 12 h after each clopidogrel LD. The initial blood drawn
as discarded to avoid measuring platelet activation induced
y needle puncture; blood was collected into a Vacutainer
ontaining 3.8% trisodium citrate and filled to capacity. The
acutainer was inverted 3 to 5 times for gentle mixing and
ent immediately to the hemostasis laboratory.
VASP index phosphorylation analysis was performed
ithin 24 h of blood collection by an experienced investi-
ator using Platelet VASP kits (Diagnostica Stago,
snières, France) as previously described (4). Briefly, a
itrated blood sample was incubated with prostaglandin E1
PGE1) or with PGE1 and ADP 10 mol/l for 10 min and
xed with paraformaldehyde, after which the platelets were
ermeabilized with nonionic detergent. Analyses were per-
ormed on an EPICS XL-MCL flow cytometer (Beckman
oultronics, Margency, France), the platelet population was
dentified from its forward and side scatter distribution, and
0,000 platelets were gated. A PRI VASP index was
alculated from the median fluorescence intensity (MFI) of
amples incubated with PGE1 or PGE1 and ADP accord-
ng to the formula: PRI VASP index  [(MFI(PGE1) 
FI(PGE1ADP))/MFIPGE1]  100. HTPR was defined as
VASP index 50% according to the consensus article (9).
ose adjustment strategy. The VASP index was mea-
ured at least 6 h and within 12 h after the first 600-mg LD
f clopidogrel. Patients with a VASP index 50% after the
lopidogrel LD were considered good responders. Patients
ith a VASP index 50% despite the 600-mg LD were
onsidered to have HTPR. For those patients, clopidogrel
re-treatment was adjusted individually, before PCI, to
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
BMI  body mass index
CI  confidence interval
CYP  cytochrome
HTPR  high on-treatment
platelet reactivity
LD  loading dose
MFI  median fluorescence
intensity
OR  odds ratio
PCI  percutaneous
coronary intervention
PCR  polymerase chain
reaction
PGE1  prostaglandin E1
PRI  platelet reactivity
inhibition
VASP  vasodilator-
stimulated phosphoproteinbtain a VASP index 50%, as previously described
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Clopidogrel Dose Adjustment in 2C19*2 Carriers November 9, 2010:1630–615,16). Briefly, as many as 3 additional LDs of 600 mg
ere prescribed 24 h after the previous dose, and the VASP
ndex was assessed 12 h after each administration until a
ASP index 50% was obtained. If these 3 additional
oluses were unable to decrease the VASP index to 50%,
atients were considered to have a failed dose adjustment.
enetic polymorphisms. Whole blood for genotyping was
btained from the arterial sheath of all patients directly after
iagnostic angiography. Genomic DNA was extracted from
eripheral blood lymphocytes by using standard procedures.
he variant was genotyped in a reaction using amplification
efractory mutation system polymerase chain reaction
PCR). The primers (Invitrogen, Carlsbad, California) are
*: forward: CAg AgC TTg gCA TAT TgT ATC; 2*
everse: TAT CgC AAg CAg TCA CAT AAC; *2 G
pecific (sens): ACT ATC ATT gAT TAT TTC CCg; and
* A specific (antisens): gTA ATT TgT TAT ggg TTC
T. The size of the PCR products generated are CYP2C19*2
orward/reverse: 373 pb, 2* G (normal allele): 283 pb, and 2* A
mutated) allele: 129 pb.
Reactions were made in a final volume of 12.5 l, using
00 nM of primer except for 2* A primer (300 nM), 0.15
nit of Taq DNA polymerase (Qbiotaq, MP Biomedicals
nc., Cleveland, Ohio) in its accompanying buffer and 200
M of accompanying deoxyribonucleoside triphosphate.
ycling conditions consisted of a touch down program: the
rst denaturing step was 1 min 30 s at 94°C, then 10 cycles
f 30 s at 94°C, 30 s at 65°C, and 50 s at 72°C followed by
0 cycles with a decrease of 0.5°C per cycle for annealing
emperature; then 15 cycles with an annealing temperature
f 60°C (the rest of the program does not change); and then
final extension step of 3 min at 72°C and cooling to 15°C.
PCR products were run on 2% agarose gels, and geno-
ypes were assigned according the PCR product sizes
bserved. The sequence variation c.681GA in the
YP2C19 gene was screened to determine the presence of
he wild-type allele or 2*. Base numbering and allele
efinitions follow the nomenclature of the Human Cyto-
hrome P450 (CYP) Allele Nomenclature Committee ac-
ording to den Dunnen recommendations.
The study protocol was approved by the ethics committee
f our institution, and patients gave written informed
onsent for participation.
tatistical analysis. All statistical analyses were performed
sing SPSS version 17.0 software (SPSS Inc., Chicago, Illi-
ois). Continuous variables are expressed as mean  SD.
ategorical variables are expressed as frequencies and percent-
ges. The usual 2-sided tests were used to compare continuous
haracteristics (Student t test) and qualitative characteristics
chi-square test) between patients carrying or not carrying the
YP2C19*2 allele and between patients with a good response
o clopidogrel and those with HTPR.
After univariate analyses, forward stepwise logistic regres-
ion models were constructed to identify factors indepen-
ently associated with HTPR. This forward approach was
ased on the log-likelihood ratio test (entry threshold: p 
.05). Age, sex, body mass index (BMI), and 2C19*2 allele narriage (homozygotic for wild-type alleles vs. 2C19*2 car-
iers) when appropriate were considered eligible to enter in
he multiple logistic regression models.
esults
tudy population. Between January 2009 and January
010, 411 patients met the inclusion criteria. The baseline
haracteristics of the study population are summarized in
able 1. The vast majority were men (78.1%) with an age of
2.9  12.2 years. The prevalence of cardiovascular risk
actors was high, including diabetes mellitus (34.8%) and
urrent smoking (37.5%).
The VASP index after the 600-mg clopidogrel LD was 53.2
23.2%. Using the 50% cutoff value for HTPR, 62.5% of
atients were considered to have HTPR.
enotyping and PR. Among the 411 patients, 134
35.3%) carried at least 1 loss-of-function 2C19*2 allele.
here were 11 homozygotic (2.7%) and 123 heterozygotic
32.6%) patients (Table 2). The genotype distributions were
n Hardy-Weinberg equilibrium.
The VASP index in patients carrying at least 1 mutant
llele was significantly higher than that of wild-type allele
omozygotes (61.7  18.4% vs. 49.2  24.2%; p  0.001).
he prevalence of HTPR among carriers of the CYP2C19*2
llele was 77% (79% for heterozygotes [97 of 123] and 54%
or homozygotes [6 of 11]) compared with 55.6% for
atients carrying the wild-type genotype (154 of 277) (p 
.0001).
In multivariate analysis, factors associated with HTPR in
he overall population were age (odds ratio [OR]: 0.97, 95%
I: 0.95 to 0.99; p 0.001) per 1-year decrease, BMI (OR:
.09, 95% CI: 1.03 to 1.14; p  0.001) per 1-U increase,
nd 2C19*2 allele carriage (OR: 2.69, 95% CI: 1.66 to 4.36;
 0.0001).
In carriers of the loss-of-function polymorphism, the only
ndependent predictor of HTPR was BMI with an OR of
.15 (95% CI: 1.04 to 1.28; p  0.007).
mpact of dose adjustment in patients homozygotic for
he wild-type alleles. Among the 277 patients carrying no
oss-of-function alleles, 123 were good responders and 154
ere considered to have HTPR (55.6%). After as many as 3
dditional 600-mg LDs of clopidogrel, 137 patients (89%)
eached a PRI 50%. Dose adjustment according to PRI
onitoring failed in 17 patients (11%) (Fig. 3C).
In multivariate analysis, the only independent predictors
f failed dose adjustment was BMI with an OR of 1.12
95% CI: 1.03 to 1.22; p  0.009) per a 1-U increase.
mpact of repeat clopidogrel LDs on HTPR patients
arrying the 2C19*2 loss-of-function allele. Among the
03 patients carrying at least 1 2C19*2 allele and who had
TPR (VASP index50%), all underwent a second LD of
lopidogrel. The VASP index was significantly decreased
fter this second clopidogrel bolus (69.7 10.1% vs. 50.6
7.6%; p  0.0001) (Fig. 3).
Four patients dropped out of the study because they couldot follow the therapeutic protocol (2 withdrew consent
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November 9, 2010:1630–6 Clopidogrel Dose Adjustment in 2C19*2 Carriersfter the second LD and 2 had nausea related to clopidogrel
ntake).
Among the remaining 99 patients carrying at least 1
utant allele and exhibiting HTPR after the first clopi-
ogrel LD, 87 patients (88%) reached a PR 50% with as
any as 3 additional 600-mg LDs of clopidogrel. Twelve
atients (12%) failed to reach this level of PRI despite 2,400
g clopidogrel in 4 days (1 homozygotic [1 of 6] and 11
eterozygotic [11 o 93]) (Fig. 2).
The dose required in these patients was 1,400  600 mg
n both homozygotes and heterozygotes.
Among patients carrying the 2C19*2 loss of function
llele, the only factor associated with failed dose adjustment
inability of as many as four 600-mg LDs of clopidogrel to
chieve a VASP index50%) was BMI (OR: 1.12, 95% CI:
.01 to 1.24; p  0.025) per a 1-U increase.
n-hospital outcome. In-hospital outcomes are described
n Table 3. Two thrombotic events were recorded: 1 stroke
fter PCI (in a wild-type allele carrier with successful dose
djustment) and 1 subacute stent thrombosis (in a patients
Baseline Characteristics of the Study PopulatioTable 1 Baseline Characteristics of the Stu
Characteristic
All Patients
(n  411)
W
Age, yrs 62.9 12.2
Men 321 (78.1)
BMI, kg/m2 27.2 4.5
Family history of CAD 66 (16.1)
Smoker 154 (37.5)
Hypercholesterolemia* 218 (53)
Diabetes mellitus 143 (34.8)
Hypertension† 243 (59.1)
Calcium-channel blocker 65 (15.8)
Proton pump inhibitor 65 (15.8)
No. of diseased vessels 1.8 0.8
VASP-1, % 53.2 23.2
Leukocytes, g/l 8.5 2.6
Hemoglobin, g/dl 13.3 2
Platelets, 103/l 228 68
Fibrinogen, g/l 3.8 1.1
Creatinine, mol/l 92 47
Values are mean  SD or n (%). *Includes patients with a previously d
diet or medication. A new diagnosis can be made during this hospit
patients with elevated triglycerides. †Includes patients with a previou
made during hospitalization, with an elevated blood pressure 140/9
BMI  body mass index; CAD  coronary artery disease; VASP  v
epartition of Genetic Polymorphisms ofytochrome 2C19*2 According to Their Responseo he F rst Loadi g Dose of Clop dogrel
Table 2
Reparti ion f Genetic Polymorphisms of
Cytochrome 2C19*2 According to Their Response
to the First Loading Dose of Clopidogrel
Variable
All Patients
(n  411)
GR
(n  154)
HTPR
(n  257) p Value
CYP2C19*2
2/2 11 (2.7%) 5 6
wt/2 123 (29.9%) 26 97 0.0001
wt/wt 277 (67.4%) 123 154
Value calculated for the prevalence of HTPR in wild-type homozygotes versus carriers of the
YP2C19*2 polymorphism.
GR  good responder; HTPR  high on-treatment reactivity; wt  wild type.eterozygotic for the CYP2C19*2 polymorphism in whom
ose adjustment failed). There were 4 occurrences of minor
hrombolysis In Myocardial Infarction noncoronary artery
ypass graft-related bleeding. It occurred in 4 patients
omozygotic for the wild-type genotype, among whom 3
ere good responders and 1 had successful dose adjustment.
o patient had coronary artery bypass surgery.
Figure 2 Impact of Repeated Clopidogrel LD
on PRI in Mutant Allele Carriers
Reduction of platelet reactivity in 2C19*2 carriers exhibiting high on-treatment
platelet reactivity after a second 600-mg LD of clopidogrel. PRI  platelet reac-
tivity inhibition; other abbreviations as in Figure 1.
pulation
pe Genotype
 277)
Mutant Carriers
(n  134) p Value
 12.2 62.4 12.3 0.9
3 (80.5) 98 (73.1) 0.1
 4.4 27.6 4.7 0.6
4 (15.9) 22 (16.4) 0.9
2 (36.8) 52 (38.8) 0.7
8 (53.4) 70 (50.2) 0.8
0 (32.5) 53 (39.6) 0.2
0 (57.8) 83 (61.9) 0.4
2 (15.2) 23 (17.2) 0.6
8 (13.7) 27 (20.1) 0.1
 0.8 1.9 0.8 0.9
 24.2 61.7 18.4 0.0001
 2.6 8.7 2.7 0.5
3 2 13.3 1.7 0.4
 66 233 73 0.1
 1.1 3.8 1.1 0.8
 53 89 30 0.4
ted diagnosis of hypercholesterolemia. Patients may be treated with
n, with an elevated total cholesterol 250 mg/dl. Does not include
mented diagnosis of hypercholesterolemia. A new diagnosis can be
Hg at rest.
tor-stimulated phosphoprotein.ndy Po
ild-Ty
(n
63.2
22
27.1
4
10
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9
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4
3
1.8
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13.
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he present study is the first to demonstrate that, despite
aving reduced clopidogrel metabolism, most carriers of the
oss-of-function CYP2C19*2 polymorphism can reach opti-
al PRI using a strategy of tailored LD according to PRI
onitoring. These data reinforce the potential of PRI
onitoring to improve the outcome of patients undergoing
CI for an acute coronary syndrome.
Several reports highlighted the critical role of peri-PCI
RI (1– 4). Blindt et al. (5) prospectively demonstrated
hat patients exhibiting a PRI 50% after a clopidogrel
D and undergoing PCI more often presented with early
tent thrombosis. Consistently, we and others have con-
rmed the high negative predictive value of this cutoff
alue of the VASP index to predict thrombotic events
fter PCI. This value was recently validated in a consen-
us definition of HTPR and proposed as a surrogate end
oint (4 – 6,9).
Clopidogrel is a prodrug that requires hepatic conversion
o an active metabolite to exert its antiplatelet properties.
he majority of absorbed clopidogrel (85% to 90%) is
ydrolyzed by carboxylase to an inactive metabolite, whereas
he remaining10% to 15% is metabolized by hepatic CYP
-450 isoenzymes in a 2-step process (17–19). Studies
ndicate that CYP2C19, CYP1A2, and CYP2B6 participate
n the first metabolic step, whereas CYP2C19, CYP2C9,
YP2B6, and CYP3A are responsible for the second step
17,18). This metabolic activation pathway is consistent
ith the time-dependent cumulative inhibition of ADP-
nduced platelet aggregation as observed with repeated daily
osing of clopidogrel (20–22). Previous research strongly
uggests that variable and insufficient active metabolite
eneration is the main explanation for clopidogrel response
ariability and HTPR (23). Importantly, CYP2C19 is in-
olved in both steps of clopidogrel metabolism. The 2*
oss-of-function polymorphism of this enzyme has been
hown to be associated with HTPR.
Hulot et al. (10) demonstrated that the 2C19*2 loss-of-
unction polymorphism was associated with decreased clo-
idogrel metabolism and thus reduced antiplatelet effect of
he drug. Furthermore, several studies have not only con-
rmed the negative impact of this polymorphism on the
iological effect of the drug but also its association with a
oor outcome after PCI (11–14). In the genetic substudy of
he TRITON–TIMI 38 (Trial to Assess Improvement in
herapeutic Outcomes by Optimizing Platelet Inhibition
ith Prasugrel–Thrombolysis In Myocardial Infarction 38)
rial (12), carriers of these mutant alleles receiving clopi-
ogrel had a 5-fold increase in their risk of stent thrombosis
nd major adverse cardiovascular events compared with
arriers of the wild-type genotype. More recently, Collet et
l. (11) confirmed in young patients admitted for a first
yocardial infarction the negative impact of CYP2C19*2
llele carriage. In a retrospective analysis, Simon et al. (14)
bserved a worse outcome in homozygotic but not inFigure 3 Impact of Clopidogrel LD Adjustment According to
PRI Depending on 2C19 Alleles Carriage
Effect of each additional bolus of clopidogrel on the VASP index in HTPR patients
homozygotic for CYP2C19*2 allele (B), carriers of one 2C19*2 allele (heterozy-
gotes) (A), or homozygotic for the wild-type alleles (C). The first LD is the VASP
index after the initial LD given to patients in both groups; the second LD is that
given after the second LD, and so on. Abbreviations as in Figure 1.eterozygotic patients compared with patients carrying 2
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November 9, 2010:1630–6 Clopidogrel Dose Adjustment in 2C19*2 Carriersild-type alleles. Altogether recent data suggest that both
eterozygotic and homozygotic patients have reduced clo-
idogrel metabolism and a poor prognosis after PCI.
In the present study, we observed that an increased or
ailored LD of clopidogrel according to PRI monitoring
esulted in improved PRI and reduced the rate of patients
ith HTPR for patients carrying the loss-of-function poly-
orphism. In fact, a strategy of clopidogrel LD adjustment
ccording to PRI was efficient in approximately 90% of the
tudied population. Although the number of patients ho-
ozygous for the loss-of-function polymorphism is small,
he present study further suggests that this therapeutic
trategy may be efficient in this population as well as in
eterozygotic patients. Our findings also suggest that the
emaining CYP2C19 activity in heterozygotes and that other
YPs involved in clopidogrel metabolism, in both homozy-
otes and heterozygotes, enable sufficient active metabolite
eneration when very high doses of clopidogrel are used.
ecently, poor clopidogrel metabolism related to CYP2C19*2
olymorphism carriage was highlighted by the “black box
arning” issued by the U.S. Food and Drug Administration
dvising health care professionals to consider use of other
ntiplatelet medications or alternative dosing strategies for
lopidogrel in patients carrying the CYP2C19*2 polymor-
hism (24). Our study demonstrates that higher or tailored
Ds may be used in these selected patients to enable
ptimal PRI to be achieved in both homozygotes and
eterozygotes for the loss-of-function polymorphism. We
reviously demonstrated that tailoring the clopidogrel LD
ccording to PRI monitoring to achieve a VASP index
50% results in a reduction in the rate of major adverse
ardiovascular events and stent thrombosis without in-
reased bleeding in patients undergoing PCI (15,16). Thus,
mproving PRI in 2C19*2 carriers, as found in the present
tudy using this therapeutic strategy, may be of clinical
enefit.
In the present study, we further observed that BMI was
strong independent predictor of HTPR and clopidogrel
D adjustment failure, both in the overall population and
n carriers of the loss-of-function polymorphism. This is
In-Hospital OutcomesTable 3 In-Hospital Outcomes
In-Hospital Outcome
Wild-Type Genotype
(n  277)
H
Thrombotic events
Death 0
Stent thrombosis 0
Acute coronary syndrome 0
Stroke 1 (SDA)
Urgent revascularization 0
All MACE 1
TIMI bleeding
Major 0
Minor 4
FDA  failed dose adjustment; MACE  major adverse cardiac ev
Thrombolysis In Myocardial Infarction.onsistent with previous findings, and the most plausible
yxplanation for such correlation is clopidogrel underdos-
ng (25–27). In contrast to clopidogrel, other antithrom-
otic drugs used during PCI such as heparin and glyco-
rotein IIb/IIIa inhibitors are weight adjusted. Other
echanisms leading to HTPR in overweight individuals
re increased baseline PRI and reduced CYP3A4 activity
28,29).
The results of the present study suggest that the genetic
olymorphism is not required to enable optimal PRI to be
eached in patients exhibiting HTPR because a dose-
djustment strategy according to PR monitoring is efficient
egardless of genetic status.
tudy limitations. This study is relatively small and did
ot assess the prognostic impact of the therapeutic strategy.
owever, previous studies have already demonstrated that
ose adjustment is clinically beneficial and thus PRI can be
sed as a surrogate end point. We did not assess other
enetic polymorphisms that could be involved in the bio-
ogical response to clopidogrel. However, a therapeutic
trategy that would be based on 1 genetic polymorphism
ould be very complex to perform.
onclusions
n increased or tailored clopidogrel LD according to
latelet reactivity monitoring can overcome HTPR in most
arriers of CYP2C19*2 loss-of-function polymorphism,
hich may result in reduced thrombotic risk post-PCI.
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zygotes 2C19*2
(n  123)
Homozygotes 2C19*2
(n  11) p Value
0 0 NS
1 (FDA) 0 NS
0 0 NS
0 0 NS
0 0 NS
1 0 NS
0 0 NS
0 0 NS
S  not significant; SDA  successful dose; adjustment; TIMI eteroahoo.fr.
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